Laura Chico

Stock Analyst at Wedbush

(0)
# 4459
Out of 5,329 analysts
245
Total ratings
28.37%
Success rate
-14.77%
Average return
46 Stocks
Name Action PT Current % Upside Ratings Updated
EWTX Edgewise Therapeutic...
Maintains: Outperform
43 43
16.86 155.04% 10 Apr 21, 2025
TRML Tourmaline Bio
Maintains: Outperform
42 43
17.8 141.57% 2 Mar 14, 2025
VIGL Vigil Neuroscience
Maintains: Outperform
24 13
2.56 407.81% 9 Mar 14, 2025
GOSS Gossamer Bio
Reiterates: Outperform
4 4
1.04 284.62% 4 Mar 14, 2025
OVID Ovid Therapeutics
Maintains: Outperform
4 3
0.32 837.5% 2 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
36 36
21.93 64.16% 6 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 28
5.29 429.3% 9 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 29
20.3 42.86% 14 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
6 6
7.48 -19.79% 9 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
157 147
109.01 34.85% 9 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
46 48
39.87 20.39% 12 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
3.73 328.95% 1 Dec 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
19 12
1.55 674.19% 10 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 38
24.07 57.87% 7 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
29 4
2.5 60% 3 Oct 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 25
20.39 22.61% 9 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
22
2.89 661.25% 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
210 205
122.09 67.91% 16 Sep 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 44
n/a n/a 7 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
40 48
39.55 21.37% 6 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
50 49
38.2 28.27% 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
8 7
3.6 94.44% 4 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 26
16.55 57.1% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
11 11
4.44 147.75% 13 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
42 42
13.77 205.01% 7 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
17 17
9.96 70.68% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
1435 1435
2.68 53444.78% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 31
17.75 74.65% 5 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 11
0.3 3566.67% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
4.89 2.25% 5 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
330
n/a n/a 6 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
n/a
n/a n/a 5 Sep 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
42
n/a n/a 3 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
24 5
n/a n/a 2 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
9 5
2.66 87.97% 2 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
149
22.93 547.62% 1 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
n/a n/a 1 Sep 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Feb 8, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
33
n/a n/a 1 Sep 18, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Outperform
40
n/a n/a 3 Feb 15, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
240 0
n/a n/a 2 Sep 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Outperform
36 0
n/a n/a 2 Mar 2, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
720
7.64 9324.08% 1 Jan 19, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
n/a
n/a n/a 1 Nov 16, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Strong Buy
280
22.23 1159.56% 1 Apr 21, 2017